Stryker Co. (NYSE:SYK) Stock Position Cut by Marshall & Sullivan Inc. WA

Share on StockTwits

Marshall & Sullivan Inc. WA cut its holdings in shares of Stryker Co. (NYSE:SYK) by 4.4% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 25,042 shares of the medical technology company’s stock after selling 1,148 shares during the period. Stryker comprises about 4.0% of Marshall & Sullivan Inc. WA’s portfolio, making the stock its 5th biggest position. Marshall & Sullivan Inc. WA’s holdings in Stryker were worth $5,417,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the business. Capital Investment Services of America Inc. increased its stake in Stryker by 0.6% during the third quarter. Capital Investment Services of America Inc. now owns 92,679 shares of the medical technology company’s stock worth $20,046,000 after purchasing an additional 514 shares during the period. Landsberg Bennett & Dubbaneh LLC increased its stake in Stryker by 1.5% during the third quarter. Landsberg Bennett & Dubbaneh LLC now owns 19,463 shares of the medical technology company’s stock worth $4,158,000 after purchasing an additional 291 shares during the period. Clarus Wealth Advisors increased its stake in Stryker by 71.5% during the third quarter. Clarus Wealth Advisors now owns 3,620 shares of the medical technology company’s stock worth $783,000 after purchasing an additional 1,509 shares during the period. Northside Capital Management LLC purchased a new stake in Stryker during the third quarter worth about $289,000. Finally, Abner Herrman & Brock LLC purchased a new stake in Stryker during the third quarter worth about $2,719,000. Institutional investors own 72.95% of the company’s stock.

A number of analysts recently weighed in on the stock. ValuEngine lowered shares of Stryker from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. Cantor Fitzgerald upped their target price on shares of Stryker from $190.00 to $230.00 and gave the stock a “neutral” rating in a research note on Friday, July 26th. Canaccord Genuity upped their target price on shares of Stryker from $195.00 to $233.00 and gave the stock a “buy” rating in a research note on Friday, July 26th. Zacks Investment Research upgraded shares of Stryker from a “hold” rating to a “buy” rating and set a $225.00 target price on the stock in a research note on Monday, July 29th. Finally, BMO Capital Markets set a $216.00 target price on shares of Stryker and gave the stock a “hold” rating in a research note on Friday, July 26th. Six investment analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. Stryker has a consensus rating of “Buy” and an average price target of $214.89.

In other Stryker news, Director Allan C. Golston sold 3,399 shares of the stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $209.84, for a total value of $713,246.16. Following the transaction, the director now directly owns 13,762 shares in the company, valued at $2,887,818.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Timothy J. Scannell sold 4,666 shares of the stock in a transaction that occurred on Tuesday, July 16th. The shares were sold at an average price of $205.88, for a total transaction of $960,636.08. Following the completion of the transaction, the insider now owns 155,963 shares in the company, valued at $32,109,662.44. The disclosure for this sale can be found here. Insiders sold 51,637 shares of company stock worth $11,240,206 over the last quarter. 7.20% of the stock is currently owned by insiders.

Shares of Stryker stock opened at $213.81 on Friday. The firm has a market capitalization of $78.89 billion, a P/E ratio of 29.25, a P/E/G ratio of 2.56 and a beta of 0.81. Stryker Co. has a 52 week low of $144.75 and a 52 week high of $223.45. The company has a quick ratio of 1.26, a current ratio of 2.07 and a debt-to-equity ratio of 0.67. The firm’s 50 day moving average is $216.98 and its two-hundred day moving average is $203.00.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, July 25th. The medical technology company reported $1.98 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.93 by $0.05. The company had revenue of $3.65 billion for the quarter, compared to analyst estimates of $3.60 billion. Stryker had a net margin of 24.99% and a return on equity of 25.98%. The firm’s revenue was up 9.9% on a year-over-year basis. During the same period in the prior year, the firm posted $1.76 earnings per share. As a group, research analysts expect that Stryker Co. will post 8.21 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 31st. Shareholders of record on Monday, September 30th will be paid a $0.52 dividend. The ex-dividend date of this dividend is Friday, September 27th. This represents a $2.08 annualized dividend and a yield of 0.97%. Stryker’s dividend payout ratio is currently 28.45%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.

See Also: How to Invest in Stocks with Increasing Dividends

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.